PGEN · available-data snapshot
Precigen, Inc. (PGEN): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Precigen, Inc. (PGEN); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for PGEN?
We do not publish a fair value for Precigen, Inc.. What we can say from its filings and market data is below.
What is PGEN's TickerWorth Score?
Priced far above peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: looks expensive on the numbers.
- Value · 7 of 100
Cheaper than 7% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 34 of 100
More profitable than 34% of Healthcare companies in US
- Financial health · 42 of 100
Financially stronger than 42% of Healthcare companies in US
- Growth · 100 of 100
Growing faster than virtually every one of the Healthcare companies in US
- Momentum · 59 of 100
Outperformed 59% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $6.45
- Market cap
- $2,
297, 713, 408 - 52-week high
- $8.98
- 52-week low
- $3.04
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Precigen, Inc. (PGEN) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, PGEN trades at a recent price of $6.45, a market capitalisation of about $2,297,713,408, sitting 57% of the way up its 52-week range ($3.04–$8.98), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing PGEN's trading multiples against a sector benchmark. Here that gives P/B of 52.8× (richer than the peer median of 7.9×); P/S of 26.8× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. PGEN shows a price-to-book (P/B) of 52.83 and book value of $0.12 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. PGEN is in a mixed trend, trading -28.2% from its 52-week high. Over the past year the stock is +62.2%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
PGEN vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | PGEN | Peer median | Read |
|---|---|---|---|
| P/B | 52.8× | 7.9× | richer than |
| P/S | 26.8× | 6.2× | richer than |
What does Precigen, Inc. do?
What does it do?
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 160 people.
How does it make money?
The business turns $86M in annual revenue into profit. Out of every $100 of sales, about $41 is left as operating profit (operating margin of 41.2%), after a 53% gross margin on the products/services it sells. After all costs, taxes and interest, -184.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries heavy debt (2.3× equity), comfortably covers its short-term bills (4.6× current ratio), and is currently lossmaking.
Who at PGEN filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Thomasian Harry Jr. | Chief Financial Officer | Option exercise | $50,711.68 | Form 4 for Thomasian Harry Jr. (opens sec.gov in a new tab) | |
| Thomasian Harry Jr. | Chief Financial Officer | Option exercise | $99,998.94 | Form 4 for Thomasian Harry Jr. (opens sec.gov in a new tab) | |
| Thomasian Harry Jr. | Chief Financial Officer | Option exercise | $1.92 | Form 4 for Thomasian Harry Jr. (opens sec.gov in a new tab) | |
| Thomasian Harry Jr. | Chief Financial Officer | Option exercise | $1.21 | Form 4 for Thomasian Harry Jr. (opens sec.gov in a new tab) | |
| KINDLER JEFFREY B | Director | Open-market sale | $1,376,400.00 | Form 4 for KINDLER JEFFREY B (opens sec.gov in a new tab) | |
| Shah Rutul R | Chief Operating Officer | Option exercise | $35,746.86 | Form 4 for Shah Rutul R (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.